Ace Therapeutics Advances Anti-Obesity Drug Discovery with Industry Leading Obesity CRO Services

New York, United States – Ace Therapeutics, a premier provider of preclinical contract research services focused on obesity and metabolic disorders, today reinforces its position as a trusted partner for biotech and pharmaceutical innovators with its comprehensive obesity CRO services. Leveraging a decade of translational pharmacology experience, Ace Therapeutics combines advanced in vivo pharmacology, real-time behavioral monitoring, and multi-dimensional biomarker analysis to transform obesity research into actionable insights for next-generation metabolic therapies.

Obesity, a chronic metabolic disorder defined by a BMI ≥30 kg/m² (per WHO criteria), is linked to increased risks of type 2 diabetes, cardiovascular diseases, and neurodegenerative disorders. With breakthroughs in therapies such as GLP-1 receptor agonists (e.g., Semaglutide) and dual GLP-1/GIP agonists driving demand for rigorous preclinical validation, Ace Therapeutics’ obesity CRO services are tailored to address the unique challenges of evaluating anti-obesity drug candidates—including those targeting GLP-1 pathways.

A cornerstone of Ace Therapeutics’ offerings is its portfolio of validated, disease-relevant preclinical models, which include the Humanized GLP-1R Mouse Model—a CRISPR-Cas9-engineered model that replaces murine GLP-1R with the human receptor. This model reduces cross-species reactivity discrepancies, enabling precise species-specific pharmacodynamic profiling and target engagement studies for GLP-1-focused therapeutics. Validated using clinically relevant reference compounds (e.g., 15% body weight reduction at clinical equivalent doses), it is a centerpiece of Ace Therapeutics’ GLP-1 preclinical CRO capabilities. Additional models include Diet-Induced Obesity (DIO) mice and rats (optimized for testing GLP-1 agonists and dual receptor agonists), ob/ob mice (for leptin-independent pathway research), and Zucker Fatty Rats (for comorbidity-focused studies), all designed to replicate human pathophysiology and meet global regulatory standards.

Beyond model access, Ace Therapeutics’ obesity CRO services encompass end-to-end solutions for drug development: from phenotypic profiling and lead optimization to safety pharmacology and mechanism of action (MoA) studies. The company’s multi-dimensional MoA research dissects both central (CNS) and peripheral pathways, utilizing technologies such as automated metabolic cage systems for real-time feeding behavior analysis, indirect calorimetry for energy expenditure profiling, and fiber photometry for neurocircuitry mapping. Its biomarker analysis platform—spanning ELISA, LC-MS/MS, RNA sequencing, and 16S rRNA sequencing—quantifies key metabolic, inflammatory, and neuroendocrine markers critical to evaluating GLP-1 and other anti-obesity therapies.

Ace Therapeutics also offers tailored support for diverse therapeutic modalities, including peptide/protein therapeutics (e.g., GLP-1 analogs), small molecules, cell and gene therapies, and multi-target agents. Its flexible, client-centric approach allows for customized study designs—from specialized diets to comorbidity induction (e.g., NAFLD, hypertension)—and mid-study adjustments to address emerging hypotheses, without compromising timelines or data integrity. All studies are conducted in-house under BSL-2 protocols, ensuring compliance with strict regulatory and ethical standards.

For biotech and pharmaceutical companies seeking to advance anti-obesity candidates—whether targeting GLP-1 pathways, novel receptors, or combination therapies—Ace Therapeutics’ obesity CRO services provide a trusted, comprehensive solution to streamline preclinical research and drive therapeutic innovation.

About Ace Therapeutics

Ace Therapeutics is a leading provider of preclinical contract research services focused on obesity and metabolic disorders. With a decade of experience in translational pharmacology, the company offers validated preclinical models, mechanism of action studies, biomarker analysis, and customized drug development solutions to biotech and pharmaceutical innovators worldwide. Ace Therapeutics’ mission is to accelerate the development of next-generation metabolic therapies through rigor, innovation, and client-centric collaboration.

For Media Contact

Contact Name: Daisy Mostert

Contact Email: contact@acetherapeutics.com

Contact Phone: 1-516-441-0167

Website: https://www.acetherapeutics.com/obesity/

Follow Us on: Facebook Twitter LinkedIn

Address: Hauppauge, NY 11788, USA